Project Grant R41AI195230
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,644 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to L2 Diagnostics LLC, a for-profit company in Woodbridge, Connecticut. The grant supports the development of a novel mosquito-targeted vaccine to disrupt the transmission cycle of malaria. The prototype vaccine candidate aims to block the development of Plasmodium parasites in mosquitoes by targeting four...
- This $412,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of South Florida to evaluate immunodominant fragments of the PfGARP antigen for the development of a malaria vaccine. The project aims to identify smaller recombinant PfGARP fragments that can generate functional antibodies and growth inhibition activity comparable to the full-length PfGARP-A antigen. The...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) totaling $549,032 is funding research to develop a safe, effective, and cost-effective multistage malaria vaccine based on a biopolymer particle platform technology. The objective is to design biopolymer particles that can simultaneously display epitopes or antigen subdomains from various malaria parasite stages to induce broad immune responses and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $122,597 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio. The grant, which runs from January 2025 to September 2027, will support research to analyze the function and antibody-mediated inhibition of the malaria vaccine candidate PF3D7_1136200. This highly conserved Plasmodium falciparum protein is a promising...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $813,160 to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The grant aims to evaluate the protective efficacy of various vaccine antigens, including PFS25, PFS230, PFCSP, PVS25, and a chimeric PVCSP, both individually...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $310,492 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the University of Washington. The grant, titled "Understanding and Overcoming Plasmodium-Specific Immune Evasion Mechanisms," aims to investigate how Plasmodium infection influences the pre-vaccine memory B cell pool to understand why current malaria vaccines have limited efficacy in endemic areas. The research...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,330 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research aimed at improving antibody-based vaccines and therapies against Plasmodium falciparum and Plasmodium vivax malaria. The funding will support the analysis of molecular properties associated with highly potent...
- This federal Project Grant award of $708,202, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to identify targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award to Brown University will: 1) conduct a case-control study in Kenya to identify infants and children with severe malaria and matched controls, 2)...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) will support research to define the immune response to Plasmodium vaccination and test an adjuvant to boost immunity against malaria. The $205,125 award to the Hennepin Healthcare Research Institute will utilize an improved small animal model to compare vaccine responses in specific pathogen-free (SPF) mice versus...
- This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...